HARMONY BIOSCIENCES HOLDINGS, INC. Cost of Revenue
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Cost of Revenue of $63.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $63.20M, a 65.64% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $44.51M, a 39.13% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $68.55M, a 25.98% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $59.65M, a 39.44% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. cost of goods and services sold for fiscal 2025 was $198.34M, a 26.48% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. cost of goods and services sold for fiscal 2024 was $156.81M, a 29.35% increase from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. cost of goods and services sold for fiscal 2023 was $121.24M, a 45.23% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. cost of goods and services sold for fiscal 2022 was $83.48M, a 50.37% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $63.20M 10-Q · filed 2026-08-04 | $107.71M 10-Q · filed 2026-08-04 | $176.25M derived: sum of 3 quarters · filed 2026-08-04 | $235.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $44.51M 10-Q · filed 2026-05-07 | $113.06M derived: sum of 2 quarters · filed 2026-05-07 | $172.71M derived: sum of 3 quarters · filed 2026-05-07 | $210.86M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $68.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $128.19M derived: sum of 2 quarters · filed 2026-02-24 | $166.35M derived: sum of 3 quarters · filed 2026-08-04 | $198.34M 10-K · filed 2026-02-24 |
| 2025-09-30 | $59.65M 10-Q · filed 2025-11-04 | $97.80M derived: sum of 2 quarters · filed 2026-08-04 | $129.80M 10-Q · filed 2025-11-04 | $184.21M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $38.15M 10-Q · filed 2026-08-04 | $70.15M 10-Q · filed 2026-08-04 | $124.56M derived: sum of 3 quarters · filed 2026-08-04 | $167.33M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $31.99M 10-Q · filed 2026-05-07 | $86.40M derived: sum of 2 quarters · filed 2026-05-07 | $129.18M derived: sum of 3 quarters · filed 2026-05-07 | $161.32M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $54.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $97.19M derived: sum of 2 quarters · filed 2026-02-24 | $129.33M derived: sum of 3 quarters · filed 2026-02-24 | $156.81M 10-K · filed 2026-02-24 |
| 2024-09-30 | $42.78M 10-Q · filed 2025-11-04 | $74.92M derived: sum of 2 quarters · filed 2025-11-04 | $102.41M 10-Q · filed 2025-11-04 | $145.56M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $32.14M 10-Q · filed 2025-08-05 | $59.63M 10-Q · filed 2025-08-05 | $102.78M derived: sum of 3 quarters · filed 2026-02-24 | $135.08M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $27.48M 10-Q · filed 2025-05-06 | $70.64M derived: sum of 2 quarters · filed 2026-02-24 | $102.93M derived: sum of 3 quarters · filed 2026-02-24 | $127.94M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $43.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $75.45M derived: sum of 2 quarters · filed 2026-02-24 | $100.46M derived: sum of 3 quarters · filed 2026-02-24 | $121.24M 10-K · filed 2026-02-24 |
| 2023-09-30 | $32.30M 10-Q · filed 2024-10-29 | $57.30M derived: sum of 2 quarters · filed 2024-10-29 | $78.08M 10-Q · filed 2024-10-29 | $104.97M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $25.01M 10-Q · filed 2024-08-06 | $45.79M 10-Q · filed 2024-08-06 | $72.67M derived: sum of 3 quarters · filed 2025-02-25 | $95.63M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $20.78M 10-Q · filed 2024-04-30 | $47.66M derived: sum of 2 quarters · filed 2025-02-25 | $70.62M derived: sum of 3 quarters · filed 2025-02-25 | $89.55M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $26.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $49.84M derived: sum of 2 quarters · filed 2025-02-25 | $68.77M derived: sum of 3 quarters · filed 2025-02-25 | $83.48M 10-K · filed 2025-02-25 |
| 2022-09-30 | $22.96M 10-Q · filed 2023-10-31 | $41.88M derived: sum of 2 quarters · filed 2023-10-31 | $56.60M 10-Q · filed 2023-10-31 | $74.41M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $18.92M 10-Q · filed 2023-08-01 | $33.64M 10-Q · filed 2023-08-01 | $51.45M derived: sum of 3 quarters · filed 2024-02-22 | $66.06M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $14.72M 10-Q · filed 2023-05-02 | $32.53M derived: sum of 2 quarters · filed 2024-02-22 | $47.14M derived: sum of 3 quarters · filed 2024-02-22 | $59.82M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $17.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $32.42M derived: sum of 2 quarters · filed 2024-02-22 | $45.11M derived: sum of 3 quarters · filed 2024-02-22 | $55.52M 10-K · filed 2024-02-22 |
| 2021-09-30 | $14.60M 10-Q · filed 2022-11-01 | $27.29M derived: sum of 2 quarters · filed 2022-11-01 | $37.70M 10-Q · filed 2022-11-01 | $47.62M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $12.69M 10-Q · filed 2022-08-02 | $23.10M 10-Q · filed 2022-08-02 | $33.01M derived: sum of 3 quarters · filed 2023-02-21 | $40.90M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $10.41M 10-Q · filed 2022-05-03 | $20.33M derived: sum of 2 quarters · filed 2023-02-21 | $28.22M derived: sum of 3 quarters · filed 2023-02-21 | $34.67M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $17.81M derived: sum of 2 quarters · filed 2023-02-21 | $24.26M derived: sum of 3 quarters · filed 2023-02-21 | $27.74M 10-K · filed 2023-02-21 |
| 2020-09-30 | $7.89M 10-Q · filed 2021-11-09 | $14.35M derived: sum of 2 quarters · filed 2021-11-09 | $17.82M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $6.46M 10-Q · filed 2021-08-10 | $9.93M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $3.47M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $1.58M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |